GlassScriptPhysician profile
Zana Nikolla
NPI 1881827368
$6,319.78
in general payments reported to CMS, 2019-2025
31 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $243 · 2021: $696 · 2022: $1,027 · 2023: $1,354 · 2024: $915 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,376.31 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $907.16 | 2019-2025 | Xifaxan, Plenvu |
| Pfizer INC. | $435.83 | 2019-2025 | |
| Boston Scientific Corporation | $418.70 | 2019-2023 | |
| Romark Laboratories, Lc | $224.20 | 2019 | |
| Janssen Biotech, INC. | $177.07 | 2020-2025 | Stelara, Tremfya, Remicade |
| Novo Nordisk INC | $176.22 | 2021-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $175.33 | 2023-2024 | Ocaliva |
| Braintree Laboratories, INC. | $169.97 | 2019-2023 | Sutab |
| Gilead Sciences, INC. | $159.59 | 2019-2025 | |
| Genzyme Corporation | $158.64 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $140.67 | 2019-2025 | Rebyota, Clenpiq |
| Takeda Pharmaceuticals U.S.A., INC. | $109.25 | 2019-2025 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $98.38 | 2021 | |
| Celgene Corporation | $94.02 | 2022-2023 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.52 | 2019-2024 | |
| Ardelyx, INC. | $61.44 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $57.02 | 2020-2023 | |
| Olympus America INC. | $48.92 | 2024 | Hanarostent Esophagus Tts(Ccc), Endoclot Phs |
| Ironwood Pharmaceuticals, INC | $46.25 | 2023-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $38.97 | 2023-2024 | Dupixent |
| Medtronic, INC. | $29.17 | 2025 | Tyrx |
| Cook Medical LLC | $28.31 | 2019 | |
| Currax Pharmaceuticals LLC | $24.24 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.75 | 2024 | Voquezna |
| Lilly USA, LLC | $17.98 | 2025 | Omvoh |
| Alfasigma USA, INC. | $14.49 | 2021 | |
| Shionogi INC | $13.00 | 2019 | |
| Fresenius Kabi USA, LLC | $12.97 | 2023 | |
| Qol Medical, LLC | $12.16 | 2021 | |
| Ucb, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zana Nikolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.